CD4 and colorectal carcinoma: The CD4+ T cells and CD8+ T cells (absolute count and ratio) used for the evaluation of the immune status of CRC patients were not statistically different following Ut supplementation (Table 5) or chemotherapy (before treatment began versus after the sixth FOLFOX4 cycle).